Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06917339 · ClinicalTrials.gov registry record

Retrospective Analyses of TrakStar Database

A clinical trial of Depression and Obsessive - Compulsive Disorder, sponsored by Neuronetics.

Recruiting
Registry status
156,000
Enrollment target
1
Study location

NCT06917339 is a study of Depression and Obsessive - Compulsive Disorder that is actively recruiting participants, run by Neuronetics. The registered enrollment target is 156,000 participants, above the 556-participant average among 679 other Depression trials with a reported enrollment target (27958% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06917339, a study of Depression and Obsessive - Compulsive Disorder, is actively recruiting participants, sponsored by Neuronetics.

RECRUITING
Registry status
156,000 participants
Enrollment target
1
Study location

Study Summary

In this study, real-world data will be used to better understand the effects patient characteristics, symptoms and TMS protocol parameters have on clinical outcomes with NeuroStar TMS.

Interventions

  • DEVICE NeuroStar Advanced TMS Therapy System

Study Locations (1)

Pennsylvania

  • Neuronetics - Malvern

Trial Details

FieldValue
Enrollment Target 156,000 participants
Start Date 2025-02-25
Est. Completion 2035-12

Sponsor

Neuronetics

11 total trials

What the Registry Record Tells You About NCT06917339

The ClinicalTrials.gov registry entry for NCT06917339 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 156,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 556-participant average among 679 other Depression trials with a reported enrollment target (27958% higher). The listed sponsor is Neuronetics, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which NeuroStar Advanced TMS Therapy System is the first listed.

NCT06917339 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06917339 about?

NCT06917339 is a clinical study titled "Retrospective Analyses of TrakStar Database". In this study, real-world data will be used to better understand the effects patient characteristics, symptoms and TMS protocol parameters have on clinical outcomes with NeuroStar TMS.

What is the current status of trial NCT06917339?

This trial is currently recruiting. The enrollment target is 156,000 participants. The study started on 2025-02-25. Estimated completion is 2035-12.

What conditions does trial NCT06917339 study?

This clinical trial studies the following conditions: Depression, Obsessive - Compulsive Disorder, Anxiety Depression.

What interventions are being tested in trial NCT06917339?

The interventions under investigation include: NeuroStar Advanced TMS Therapy System (DEVICE).

Who is sponsoring clinical trial NCT06917339?

This trial is sponsored by Neuronetics, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06917339 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.